A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease (ISV-101)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01478555
The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers
Anticipated Study Start Date
Estimated Primary Completion Date
Estimated Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Volunteers 18 years of age and older who have a diagnosis of moderate to severe dry eye disease.
Negative pregnancy test prior to the conduct of any protocol-specific procedure. The subject must use effective contraception for the duration of the study. Post menopausal is defined as having no menses for at least 12 consecutive months
Signature of the subject on the Informed Consent Form
Willing to avoid disallowed medication for the duration of the study.
Able to self-administer study drug (or have a caregiver available to instill all doses of study drug)
Able and willing to follow study instructions
Additional inclusion criteria also apply
Females who are pregnant or nursing. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study).
Use of contact lenses during the study.
Use of any concomitant topical ocular medications except for artificial tears during the dosing period
Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents.
Prior or anticipated concurrent use of an investigational product or device that could confound the findings about Dry Eye in the study eye.
A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation
Known hypersensitivity to any component of the study drug or procedural medications
Participation in any other clinical trial within 30 days prior to screening
Known hypersensitivity to NSAIDS
Any active corneal epithelial/stromal pathology noted in the study eye at the screening visit
Any history of corneal surgery (including corneal crosslinking, radial keratotomy, corneal transplant, or LASIK)
Cataract surgery within the past year.
Known contraindication to the study drugs or any of their components